ClinicalTrials.gg
CompletedNCT02637856Updated May 26, 2020Results posted

A Study of Ocrelizumab in Participants With Relapsing Remitting Multiple Sclerosis (RRMS) Who Have Had a Suboptimal Response to an Adequate Course of Disease-Modifying Treatment (DMT)

A Phase 3 interventional study of Ocrelizumab and Ocrelizumab in Multiple Sclerosis, Relapsing-Remitting, sponsored by Genentech, Inc.. Completed at 82 sites in 2 countries. Open to participants aged 18 Years to 55 Years. Per ClinicalTrials.gov, last updated 2020-05-26.

Sponsored by Genentech, Inc. (part of Hoffmann-La Roche) · Phase 3, Interventional, and Treatment

Help build ClinicalTrials.gg — short surveys, remote interviews or testing, in your language. Take part →

Phase
Phase 3
Study type
Interventional
Enrollment
608
Allocation
Not applicable
Ages
18 Years to 55 Years
Sex
All
01

Where this study stands

Counted across the records on this site · 2026-11-17

Among 10 studies testing ocrelizumab in Multiple Sclerosis, Relapsing-Remitting — 2 open to participants now, 5 under way, 3 of them phase 3. ocrelizumab · Multiple Sclerosis, Relapsing-Remitting.

Enrollment
4th of 10
608 · median 404
Started
2016
with 1 other
Phase 3
6 of 10
1 open now
Registered
2nd of 10
by date
Lead sponsor
2 of 10
Genentech, Inc.

Among the 10 studies testing ocrelizumab in Multiple Sclerosis, Relapsing-Remitting, this one is the 4th largest by enrollment, is one of 2 that started in 2016, is one of 6 in phase 3, and was the 2nd registered.

Multiple Sclerosis, Relapsing-Remitting

618 studies on the registry are indexed under Multiple Sclerosis, Relapsing-Remitting; 83 are open to participants now.

Browse Multiple Sclerosis, Relapsing-Remitting studies →

Open to participants now

2 of the 10 studies testing ocrelizumab in Multiple Sclerosis, Relapsing-Remitting are open now, in 2 countries. Recruiting first, the newest first:

By country, each count listing its studies:

All 2 open studies →

About ocrelizumab

ocrelizumab: first FDA approval 2017 (OCREVUS), first EMA approval 2018. What it is approved for, and how studies give it, is on its page →

Who these studies take

Of the 61 Multiple Sclerosis, Relapsing-Remitting studies recruiting now, 11 (18%) set no upper age limit and 44 (72%) stop at 75 or younger; 2 take children under 18; 11 take healthy volunteers.

This study: 18 Years to 55 Years · all sexes · no healthy volunteers.

The full table on the hub →

This tab as a report to print or save as PDF → With an account.

Was this useful?
Get alerts for this landscapeDownload CSVNarrow it in search →With an account: a weekly mail of what changed among 10 studies testing ocrelizumab in Multiple Sclerosis, Relapsing-Remitting, or all of them as a file.
02

Study summary

This study will evaluate the efficacy and safety of ocrelizumab in participants with RRMS who have had a suboptimal response to an adequate course of DMT. Participants will receive ocrelizumab as an initial dose of two 300-milligrams (mg) intravenous (IV) infusions (600 mg total) separated by 14 days followed by one 600-mg IV infusion for a maximum of 4 doses (up to 96 weeks). Anticipated time on study treatment is 96 weeks.

Read the detailed description

Participants who complete their Week 72 ocrelizumab infusion and do not experience any serious infusion related reaction (IRR) throughout the main study will be eligible to enroll in an optional, open-label, non-randomized substudy to MN30035 and receive one additional shorter infusion of ocrelizumab at the Week 96 visit. This substudy will enroll approximately 100 patients from MN30035 main study.

03

Conditions studied

  • Multiple Sclerosis, Relapsing-Remitting
04

Who can participate

Ages eligible
18 Years to 55 Years
Sexes eligible
All
Accepts healthy volunteers
No

Go through the criteria one by one — yes, no or not sure — and take the list to your doctor or the study team. Kept in this browser only.

Inclusion criteria

  • Diagnosis of multiple sclerosis (specifically RRMS), in accordance with the revised 2010 McDonald criteria
  • Disease duration from first symptom of less than or equal to (\</=) 12 years
  • Treated with an adequate course of treatment with no more than three prior DMT regimens of greater than or equal to (>/=) 6 months, and the discontinuation of the most recent adequately used DMT was due to suboptimal response
  • Suboptimal response while the participant was on his/her last adequately used DMT for >/=6 months (defined by having one of the following qualifying events despite being on a stable dose of the same DMT for at least 6 months: one or more clinically reported relapses, one or more T1 Gd-enhanced lesions, or two or more new or enlarging T2 lesions on MRI); these qualifying events must have occurred while on the last adequately used DMT. In participants receiving stable doses of the same approved DMT for more than a year, the event must have occurred within the last 12 months of treatment with this DMT from the date of screening

Exclusion criteria

Exclusion Criteria:

  • History of primary progressive multiple sclerosis (PPMS), progressive relapsing multiple sclerosis (PRMS), or secondary progressive multiple sclerosis (SPMS)
  • for MRI
  • Known presence of other neurological disorders that may mimic multiple sclerosis
  • Pregnancy or lactation, or intention to become pregnant during the study
  • Requirement for chronic treatment with systemic or during the course of the study
  • History of or currently active primary or secondary immunodeficiency
  • Lack of peripheral venous access
  • History of severe allergic or anaphylactic reactions to humanized or murine monoclonal antibodies
  • Active infection, or history of or known presence of recurrent or chronic infection such as (HIV), syphilis, or tuberculosis
  • History of progressive multifocal leukoencephalopathy
  • Contraindications to or intolerance of oral or IV corticosteroids
  • Previous treatment with fingolimod (Gilenya®) or dimethyl fumarate (Tecfidera®) in participants whose lymphocyte count is below the lower limit of normal (LLN)
  • Treatment with alemtuzumab (Lemtrada®)
  • Previous treatment with systemic cyclophosphamide, azathioprine, mycophenolate mofetil, cyclosporine, or methotrexate
  • Previous treatment with natalizumab within 12 months prior to screening unless failure was due to confirmed, persistent anti-drug antibodies (ADAs). Participants previously treated with natalizumab will be eligible for this study only if duration of treatment with natalizumab was less than (\<) 1 year and natalizumab was not used in the 12 months prior to screening. Anti-John Cunningham virus (JCV) antibody status (positive or negative) and titer (both assessed within the year of screening) must be documented prior to enrollment
  • Treatment with dalfampridine (Ampyra®) unless on stable dose for >/=30 days prior to screening
  • Treatment with a B-cell targeted therapies (e.g., rituximab, ocrelizumab, atacicept, belimumab, or ofatumumab)
  • Treatment with a drug that is experimental (Exception: treatment with an experimental drug that was subsequently approved in the participant's country is allowed)
Terms in these criteria, in plain language(4)

Underlined terms in the criteria open these too. Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.

Contraindication

A reason a treatment, test or procedure should not be given to a particular person, such as an allergy, another illness or a medicine they take.

Corticosteroids (steroids)

Anti-inflammatory medicines such as prednisone, prednisolone and dexamethasone — not the anabolic steroids used for muscle.

Studies differ in what they allow: check which steroid medicines, routes (tablets, injections, creams, inhalers, eye drops) and doses this study accepts.

Immunosuppression

A weakened immune system. It can come from an illness, such as HIV or some blood cancers, or from medicines that turn the immune system down, for example after an organ transplant or for an autoimmune disease; steroids at higher doses count.

Read whether the line is about a condition or about medicines, and which medicines and doses it means.

HIV

The human immunodeficiency virus, which weakens the immune system.

Many studies now accept people whose HIV is controlled on treatment, judged by the viral load and the CD4 count. Check the limits this study sets.

05

Study design

Phase
Phase 3
Primary purpose
Treatment
Allocation
Not applicable
Intervention model
Single group
Masking
None (open label)
Enrollment
608 participants (actual)

Study arms

  • Experimental
    Ocrelizumab

    Participants will receive ocrelizumab as an initial dose of two 300-mg IV infusions (600 mg total) separated by 14 days (on Days 1 and 15) followed by one 600-mg IV infusion every 24 weeks for a maximum of 4 doses (up to 96 weeks).

    Drug: Ocrelizumab

  • Experimental
    Ocrelizumab (substudy)

    Participants with no serious IRR throughout the main study will be eligible to enroll in an optional substudy and receive one additional shorter infusion of ocrelizumab at the Week 96 visit. Ocrelizumab will be administered IV as a single 600-mg dose at a shorter infusion rate (approximately 2 hours instead of 3.5 hours)

    Drug: Ocrelizumab

Interventions

  • Participants will receive ocrelizumab as an initial dose of two 300-mg IV infusions (600 mg total) separated by 14 days (on Days 1 and 15) followed by one 600-mg IV infusion every 24 weeks for a maximum of 4 doses (up to 96 weeks).

    Also known as: RO4964913

  • Participants will receive an additional single 600-mg dose IV infusion at a shorter infusion rate (approximately 2 hours instead of 3.5 hours)

    Also known as: RO4964913

06

What researchers measure

Primary outcomes

  1. Percentage of Participants Without Any Protocol-Defined Events During 96-Week Period

    Protocol-defined event is the occurrence of either protocol-defined relapse (occurrence of new or worsening neurological symptoms attributable to multiple sclerosis) or T1 gadolinium (Gd)-enhanced lesion on brain magnetic resonance imaging (MRI) or new and/or enlarging T2 lesion on brain MRI or confirmed disability progression at 24 weeks.

    Time frame: Baseline up to Week 96

  2. Percentage of Participants With Infusion Related Reactions (IRRs) in Optional Substudy

    Rate and frequency of Grade 3 or 4 IRRs with onset on or after the shorter ocrelizumab infusion

    Time frame: Week 96 to Week 100

Secondary outcomes

  1. Percentage of Participants Without Any Protocol-Defined Events During 24-Week and 48-Week Period

    Protocol-defined event is the occurrence of either protocol-defined relapse (occurrence of new or worsening neurological symptoms attributable to multiple sclerosis) or T1 Gd-enhanced lesion on brain MRI or new and/or enlarging T2 lesion on brain MRI or confirmed disability progression at 24 weeks.

    Time frame: Baseline up to Weeks 24 and 48

  2. Time to Protocol-Defined Event

    Protocol-defined event is the occurrence of either protocol-defined relapse (occurrence of new or worsening neurological symptoms attributable to multiple sclerosis) or T1 Gd-enhanced lesion on brain MRI or new and/or enlarging T2 lesion on brain MRI or confirmed disability progression at 24 weeks.

    Time frame: Baseline up to Week 96

  3. Total Number of Protocol-Defined Relapses Per Participant Year During 96-week Period

    Protocol-defined relapse is an occurrence of new or worsening neurological symptoms attributable to multiple sclerosis which must persist for greater than (\>) 24 hours and should not be attributable to confounding clinical factors (e.g., fever, infection, injury, adverse reactions to medications) and immediately preceded by a stable or improving neurological state for least 30 days. The Adjusted Annualized Relapse Rate was adjusted by baseline Expanded Disability Status Scale (EDSS \<2.5 vs. \>=2.5) and number of previous disease-modifying treatments (DMTs =1 vs. \>1)

    Time frame: Baseline up to Week 96

  4. Time to Onset of First Protocol-Defined Relapse

    Protocol-defined relapse is an occurrence of new or worsening neurological symptoms attributable to multiple sclerosis which must persist for \>24 hours and should not be attributable to confounding clinical factors (e.g., fever, infection, injury, adverse reactions to medications) and immediately preceded by a stable or improving neurological state for least 30 days.

    Time frame: Baseline up to Week 96

  5. Time to Onset of First T1 Gd-Enhanced Lesion as Detected by Brain MRI

    Time frame: Baseline up to Week 96

  6. Time to Onset of First New and/or Enlarging T2 Lesion as Detected by Brain MRI

    Time frame: Baseline up to Week 96

  7. Time to Onset of Confirmed Disability Progression (CDP) for at Least 24 Weeks According to Expanded Disability Status Scale (EDSS) Score

    Time frame: Baseline up to Week 96

  8. Total Number of T1 Gd-Enhancing Lesions as Detected by Brain MRI

    The analyses included participants who had an interpretable MRI at the time point of interest. Participants having 0, 1, 2, 3, and greater than 3 lesions at weeks 24, 48, and 96 were included in the analysis.

    Time frame: Weeks 24, 48, and 96

  9. Change From Baseline in Total T2 Lesion Volume as Detected by Brain MRI

    Baseline data is represented as mean; post-Baseline date are represented as mean changes.

    Time frame: Baseline, Weeks 24, 48, and 96

  10. Total Number of New and/or Enlarging T2 Lesions as Detected by Brain MRI

    Time frame: Weeks 24, 48, and 96

  11. Percentage of Participants With Adverse Events

    An adverse event is any untoward medical occurrence in a subject administered a pharmaceutical product and which does not necessarily have to have a causal relationship with the treatment. An adverse event can therefore be any unfavorable and unintended sign (including an abnormal laboratory finding, for example), symptom, or disease temporally associated with the use of a pharmaceutical product, whether or not considered related to the pharmaceutical product. Preexisting conditions which worsen during a study are also considered as adverse events.

    Time frame: Baseline up to 100 weeks

07

Results

Posted May 26, 2020

Participant flow

The study was conducted in North America at 90 study sites in the U.S. and Canada.

Main Study (Baseline to Week 100)
Participant flow — Main Study (Baseline to Week 100)
MilestoneOcrelizumabOcrelizumab (Substudy)
Started6080
Completed3890
Not completed2190
Withdrew: Adverse event90
Withdrew: Lost to follow-up50
Withdrew: Physician decision20
Withdrew: Pregnancy70
Withdrew: Withdrawal by subject200
Withdrew: Protocol deviation20
Withdrew: Continued on commercial ocrevus1640
Withdrew: Failed drug test10
Withdrew: Incarceration10
Withdrew: Pregnancy attempts20
Withdrew: Site closing60
Sub-Study (Week 72 to Week 100)
Participant flow — Sub-Study (Week 72 to Week 100)
MilestoneOcrelizumabOcrelizumab (Substudy)
Started0129
Completed0125
Not completed04
Withdrew: Non-safety reason (moved out of state)01
Withdrew: Lost to follow-up03

Outcome measures

PrimaryPercentage of Participants Without Any Protocol-Defined Events During 96-Week Period

Protocol-defined event is the occurrence of either protocol-defined relapse (occurrence of new or worsening neurological symptoms attributable to multiple sclerosis) or T1 gadolinium (Gd)-enhanced lesion on brain magnetic resonance imaging (MRI) or new and/or enlarging T2 lesion on brain MRI or confirmed disability progression at 24 weeks.

Time frame:
Baseline up to Week 96
Reported as:
Number · Percentage of Participants
Percentage of Participants Without Any Protocol-Defined Events During 96-Week Period
Percentage of ParticipantsOcrelizumab
Percentage of Participants Without Any Protocol-Defined Events During 96-Week Period48.1 (43.9 to 52.3)
SecondaryPercentage of Participants Without Any Protocol-Defined Events During 24-Week and 48-Week Period

Protocol-defined event is the occurrence of either protocol-defined relapse (occurrence of new or worsening neurological symptoms attributable to multiple sclerosis) or T1 Gd-enhanced lesion on brain MRI or new and/or enlarging T2 lesion on brain MRI or confirmed disability progression at 24 weeks.

Time frame:
Baseline up to Weeks 24 and 48
Reported as:
Number · Percentage of Participants
Percentage of Participants Without Any Protocol-Defined Events During 24-Week and 48-Week Period
Percentage of ParticipantsOcrelizumab
Week 2459.0 (54.9 to 63.1)
Week 4851.2 (47.0 to 55.4)
SecondaryTime to Protocol-Defined Event

Protocol-defined event is the occurrence of either protocol-defined relapse (occurrence of new or worsening neurological symptoms attributable to multiple sclerosis) or T1 Gd-enhanced lesion on brain MRI or new and/or enlarging T2 lesion on brain MRI or confirmed disability progression at 24 weeks.

Time frame:
Baseline up to Week 96
Reported as:
Median · Weeks
Time to Protocol-Defined Event
WeeksOcrelizumab
Time to Protocol-Defined EventNA (53.86 to NA)
SecondaryTotal Number of Protocol-Defined Relapses Per Participant Year During 96-week Period

Protocol-defined relapse is an occurrence of new or worsening neurological symptoms attributable to multiple sclerosis which must persist for greater than (\>) 24 hours and should not be attributable to confounding clinical factors (e.g., fever, infection, injury, adverse reactions to medications) and immediately preceded by a stable or improving neurological state for least 30 days. The Adjusted Annualized Relapse Rate was adjusted by baseline Expanded Disability Status Scale (EDSS \<2.5 vs. \>=2.5) and number of previous disease-modifying treatments (DMTs =1 vs. \>1)

Time frame:
Baseline up to Week 96
Reported as:
Number · Number of Relapses/Participant Year
Total Number of Protocol-Defined Relapses Per Participant Year During 96-week Period
Number of Relapses/Participant YearOcrelizumab
Total Number of Protocol-Defined Relapses Per Participant Year During 96-week Period0.046 (0.036 to 0.060)
SecondaryTime to Onset of First Protocol-Defined Relapse

Protocol-defined relapse is an occurrence of new or worsening neurological symptoms attributable to multiple sclerosis which must persist for \>24 hours and should not be attributable to confounding clinical factors (e.g., fever, infection, injury, adverse reactions to medications) and immediately preceded by a stable or improving neurological state for least 30 days.

Time frame:
Baseline up to Week 96
Reported as:
Median · Weeks
Time to Onset of First Protocol-Defined Relapse
WeeksOcrelizumab
Time to Onset of First Protocol-Defined RelapseNA (NA to NA)
SecondaryTime to Onset of First T1 Gd-Enhanced Lesion as Detected by Brain MRI
Time frame:
Baseline up to Week 96
Reported as:
Median · Weeks
Time to Onset of First T1 Gd-Enhanced Lesion as Detected by Brain MRI
WeeksOcrelizumab
Time to Onset of First T1 Gd-Enhanced Lesion as Detected by Brain MRINA (NA to NA)
SecondaryTime to Onset of First New and/or Enlarging T2 Lesion as Detected by Brain MRI
Time frame:
Baseline up to Week 96
Reported as:
Median · Weeks
Time to Onset of First New and/or Enlarging T2 Lesion as Detected by Brain MRI
WeeksOcrelizumab
Time to Onset of First New and/or Enlarging T2 Lesion as Detected by Brain MRINA (NA to NA)
SecondaryTime to Onset of Confirmed Disability Progression (CDP) for at Least 24 Weeks According to Expanded Disability Status Scale (EDSS) Score
Time frame:
Baseline up to Week 96
Reported as:
Median · Weeks
Time to Onset of Confirmed Disability Progression (CDP) for at Least 24 Weeks According to Expanded Disability Status Scale (EDSS) Score
WeeksOcrelizumab
Time to Onset of Confirmed Disability Progression (CDP) for at Least 24 Weeks According to Expanded Disability Status Scale (EDSS) ScoreNA (NA to NA)
SecondaryTotal Number of T1 Gd-Enhancing Lesions as Detected by Brain MRI

The analyses included participants who had an interpretable MRI at the time point of interest. Participants having 0, 1, 2, 3, and greater than 3 lesions at weeks 24, 48, and 96 were included in the analysis.

Time frame:
Weeks 24, 48, and 96
Reported as:
Number · Number of Lesions
Total Number of T1 Gd-Enhancing Lesions as Detected by Brain MRI
Number of LesionsOcrelizumab
Week 2433 (0.010 to 0.050)
Week 4816 (0.002 to 0.031)
Week 967 (0.002 to 0.026)
SecondaryChange From Baseline in Total T2 Lesion Volume as Detected by Brain MRI

Baseline data is represented as mean; post-Baseline date are represented as mean changes.

Time frame:
Baseline, Weeks 24, 48, and 96
Reported as:
Mean · cubic centimeter (cm3)
Change From Baseline in Total T2 Lesion Volume as Detected by Brain MRI
cubic centimeter (cm3)Ocrelizumab
Baseline11.551 ± 0.590
Week 24-0.484 ± 0.118
Week 48-0.549 ± 0.123
Week 96-0.560 ± 0.129
SecondaryTotal Number of New and/or Enlarging T2 Lesions as Detected by Brain MRI
Time frame:
Weeks 24, 48, and 96
Reported as:
Number · Number of Lesions
Total Number of New and/or Enlarging T2 Lesions as Detected by Brain MRI
Number of LesionsOcrelizumab
Week 24640
Week 4839
Week 9638
SecondaryPercentage of Participants With Adverse Events

An adverse event is any untoward medical occurrence in a subject administered a pharmaceutical product and which does not necessarily have to have a causal relationship with the treatment. An adverse event can therefore be any unfavorable and unintended sign (including an abnormal laboratory finding, for example), symptom, or disease temporally associated with the use of a pharmaceutical product, whether or not considered related to the pharmaceutical product. Preexisting conditions which worsen during a study are also considered as adverse events.

Time frame:
Baseline up to 100 weeks
Reported as:
Number · Percentage of Participants
Percentage of Participants With Adverse Events
Percentage of ParticipantsOcrelizumab
Percentage of Participants With Adverse Events86.3
PrimaryPercentage of Participants With Infusion Related Reactions (IRRs) in Optional Substudy

Rate and frequency of Grade 3 or 4 IRRs with onset on or after the shorter ocrelizumab infusion

Time frame:
Week 96 to Week 100
Reported as:
Number · Percentage of Participants
Percentage of Participants With Infusion Related Reactions (IRRs) in Optional Substudy
Percentage of ParticipantsOcrelizumab (Substudy)
Percentage of Participants With Infusion Related Reactions (IRRs) in Optional Substudy0 (0.0 to 2.8)

Adverse events

Collected over Baseline up to 100 weeks. Non-serious events are listed at a 5% frequency threshold.

Adverse event summary by group
GroupDeathsSeriousOther
Ocrelizumab0/608 (0%)47/608 (7.7%)406/608 (66.8%)
Ocrelizumab (Substudy)0/129 (0%)2/129 (1.6%)16/129 (12.4%)
Most frequent serious events
Showing 10 of 45
Most frequent serious events
EventOcrelizumabOcrelizumab (Substudy)
Muscle spasmsMusculoskeletal and connective tissue disorders1/6081/129
NeoplasmNeoplasms benign, malignant and unspecified (incl cysts and polyps)1/6081/129
AppendicitisInfections and infestations3/6080/129
Multiple sclerosis relapseNervous system disorders3/6080/129
Suicidal ideationPsychiatric disorders3/6080/129
Cholecystitis acuteHepatobiliary disorders2/6080/129
PyelonephritisInfections and infestations2/6080/129
Urinary tract infectionInfections and infestations2/6080/129
EncephalopathyNervous system disorders2/6080/129
SeizureNervous system disorders2/6080/129
Most frequent other events
Most frequent other events
EventOcrelizumabOcrelizumab (Substudy)
Infusion related reactionInjury, poisoning and procedural complications263/60816/129
Urinary tract infectionInfections and infestations88/6080/129
NasopharyngitisInfections and infestations64/6080/129
FatigueGeneral disorders58/6080/129
Upper respiratory tract infectionInfections and infestations57/6080/129
HeadacheNervous system disorders56/6080/129
SinusitisInfections and infestations37/6080/129
Pain in extremityMusculoskeletal and connective tissue disorders36/6080/129
NauseaGastrointestinal disorders32/6080/129

Baseline characteristics

Age, Continuous
Age, Continuous(Years)Ocrelizumab
Mean37.2 ± 8.6
Sex: Female, Male
Sex: Female, Male(Participants)Ocrelizumab
Female438
Male170
Race/Ethnicity, Customized
Race/Ethnicity, Customized(Participants)Ocrelizumab
Hispanic or Latino68
Not Hispanic or Latino526
Not Stated7
Unknown7
Race/Ethnicity, Customized
Race/Ethnicity, Customized(Participants)Ocrelizumab
American Indian or Alaska Native2
Asian13
Black or African American72
Multiple6
Native Hawaiian or other Pacific Islande3
Unknown17
White495
08

Study locations

82 sites
  • North Central Neurology Associates
    Cullman, Alabama 35058, United States
  • Phoenix Neurological Associates Ltd
    Phoenix, Arizona 85006, United States
  • Barrow Neurological Institute
    Phoenix, Arizona 85013, United States
  • Territory Neurology and Research Institute
    Tucson, Arizona 85704, United States
  • The Research Center of Southern California, LLC
    Carlsbad, California 92011, United States
  • Mercy Medical Group; MS Centre Nurse
    Carmichael, California 95608, United States
  • Fullerton Neurology and Headache Center
    Fullerton, California 92835, United States
  • Scripps Health
    La Jolla, California 92037, United States
  • UCSF- Multiple Sclerosis Centre; Department of Neurology
    San Francisco, California CA94158, United States
  • Los Angeles Biomedical Research Institute at Harbor-UCLA Medical Center
    Torrance, California 90502, United States
  • Mountain Neurological Research Center; Roaring Fork Neurologt, P.C.
    Basalt, Colorado 81621, United States
  • IMMUNOe Research Centers
    Centennial, Colorado 80112, United States
  • Colorado Neurological Institute
    Englewood, Colorado 80113, United States
  • Advanced Neurology of Colorado, LLC
    Fort Collins, Colorado 80528, United States
  • Associated Neurologists of Southern CT PC
    Fairfield, Connecticut 06824, United States
  • KI Health Partners, LLC; New England Institute for Clinical Research
    Stamford, Connecticut 06905, United States
  • Neurology Associates PA
    Maitland, Florida 32751, United States
  • University of Miami Miller School of Medicine; Clinical Reseach Building
    Miami, Florida 33136, United States
  • Neurostudies Inc
    Port Charlotte, Florida 33952, United States
  • Infinity Clinical Research, LLC
    Sunrise, Florida 33351, United States
  • Axiom Clinical Research of Florida
    Tampa, Florida 33609, United States
  • University of South Florida - Bradenton
    Tampa, Florida 33612, United States
  • Ms Center Of Atlanta
    Atlanta, Georgia 30327, United States
  • University of Chicago Hospital
    Chicago, Illinois 60637, United States
  • Consultants in Neurology Ltd
    Northbrook, Illinois 60062, United States
  • American Health Network Institute, LLC
    Avon, Indiana 46123, United States
  • Josephson Wallack Munshower Neurology PC
    Indianapolis, Indiana 46256, United States
  • University of Kansas Medical Center; Division of Nuclear Medicine
    Kansas City, Kansas 66160, United States
  • Lahey Clinic Med Ctr
    Lexington, Kentucky 02421, United States
  • Associates in Neurology PSC
    Lexington, Kentucky 40513, United States
  • Community Medical Associates Inc.; d.b.a. Norton Neurology Services MS Services
    Louisville, Kentucky 40207, United States
  • Ochsner Clinic Foundation
    New Orleans, Louisiana 70121, United States
  • University of Maryland Medical Center; Department of Neurology
    Baltimore, Maryland 21201, United States
  • John Hopkins University School of Medicine
    Baltimore, Maryland 21287, United States
  • Massachusetts General Hospital
    Boston, Massachusetts 02114, United States
  • Beth Israel Deaconess Med Ctr; Neurology/MS Center
    Boston, Massachusetts 02215, United States
  • Dragonfly Research, LLC
    Wellesley, Massachusetts 02481, United States
  • UMASS Memorial Medical Center
    Worcester, Massachusetts 01655, United States
  • Wayne State University; Department of Neurology
    Detroit, Michigan 48201, United States
  • Minneapolis Clinic of Neurology
    Golden Valley, Minnesota 55422, United States
  • Washington University School of Medicine; Department of Neurology
    Saint Louis, Missouri 63110, United States
  • Cleveland Clinic Lou Ruvo; Center for Brain Research
    Las Vegas, Nevada 89106, United States
  • Rutgers New Jersey Medical School
    Newark, New Jersey 07103, United States
  • Holy Name Hospital; Institute For Clinical Research
    Teaneck, New Jersey 07666, United States
  • Jacobs Neurological Institute
    Buffalo, New York 14203, United States
  • The MS Center of Northeastern New York
    Latham, New York 12110, United States
  • Columbia University Medical Center
    New York, New York 10032, United States
  • South Shore Neurologic Associates P.C.
    Patchogue, New York 11772, United States
  • Island Neurological Associates, P.C.
    Plainview, New York 11803, United States
  • Raleigh Neurology Associates
    Raleigh, North Carolina 27607-6520, United States
  • UC Health Clinical Trials Office
    Cincinnati, Ohio 45267, United States
  • Cleveland Clinic Foundation; Cleveland Clinic Cancer Center/I40
    Cleveland, Ohio 44195, United States
  • The Ohio State University Wexner Medical Center; Department of Neurology
    Columbus, Ohio 43210, United States
  • Neurology Specialists, Inc
    Dayton, Ohio 45417, United States
  • Neurology and Neuroscience Assoc., Inc.
    Westerville, Ohio 43081, United States
  • Oklahoma Medical Research Foundation
    Oklahoma City, Oklahoma 73104, United States
  • Providence Multiple Sclerosis Center
    Portland, Oregon 97225, United States
  • Allegheny Neurological Associates
    Pittsburgh, Pennsylvania 15212, United States
  • Neurology Clinic PC
    Cordova, Tennessee 38018, United States
  • Hope Neurology
    Knoxville, Tennessee 37922, United States
  • Uni of Texas Health Science Center At Houston
    Houston, Texas 77030, United States
  • Bhupesh Dihenia M.D. P.A.
    Lubbock, Texas 79410, United States
  • Central Texas Neurology Consultants
    Round Rock, Texas 78681, United States
  • Neurology Center of San Antonio
    San Antonio, Texas 78212, United States
  • Rocky Mountain MS Clinic
    Salt Lake City, Utah 84103, United States
  • Swedish Neuroscience Institute
    Seattle, Washington 98122, United States
  • MultiCare Health System Institute for Research and Innovation
    Tacoma, Washington 98405, United States
  • Foothills Medical Centre; Centre Dept of Medical Clinical Neuroscience
    Calgary, Alberta T2N 2T9, Canada
  • University of Alberta; Divison of Pulmonary Medicine, Dept. of Medicine,
    Edmonton, Alberta T6C 2G3, Canada
  • Fraser Health Multiple Sclerosis Clinic; Burnaby Hospital Pharmacy
    Burnaby, British Columbia V5G 2X6, Canada
  • Horizon Health Network - Multiple Sclerosis Clinic
    Saint John, New Brunswick E2L 4L2, Canada
  • Dalhousie Multiple Sclerosis Research Unit
    Halifax, Nova Scotia B3H 4K4, Canada
  • Hamilton General Hospital
    Hamilton, Ontario L8L 2X2, Canada
  • The Ottawa Hospital - General Campus; Department of Neurology - Multiple Sclerosis
    Ottawa, Ontario K1H 8L6, Canada
  • St. Michael's Hospital MS Clinic, MS Research Centre
    Toronto, Ontario, Canada
  • Clinique NeuroOutaouais
    Gatineau, Quebec J8Y 1W2, Canada
  • Recherche Sepmus, Inc.
    Greenfield Park, Quebec J4V 2J2, Canada
  • Hopital Hotel Dieu de Levis
    Levis, Quebec G6V 3Z1, Canada
  • Chum Campus Notre Dame
    Montreal, Quebec H2X 0A9, Canada
  • McGill University; Montreal Neurological Institute; Neurological and Psychiatric
    Montreal, Quebec H3A 2B4, Canada
  • MS Clinic Mauricie Bois Francs
    Trois Rivieres, Quebec G8Z 3R9, Canada
  • CHU De Quebec Universite Laval
    Quebec, G1J 1Z4, Canada
09

References and documents

Study documents

PDFs hosted by the registry, ClinicalTrials.gov.

10

Timeline

Tracking since Sep 25, 2026
ElapsedEstimatedEstimated, not yet reachedSimilar studies: half by the dot; the band is the middle halfHalf of similar studies reached it by the dot; the band is the middle half, from a quarter to three quarters

Ran from Feb 2016 to primary completion in May 2019, 38 months.

Results were first posted in May 2020, 1 year after primary completion.

Of 28 industry-sponsored phase 3 interventional studies under Multiple Sclerosis, Relapsing-Remitting, half reached primary completion within 38 months of starting (the median), counting those still running; a quarter within 26 and three quarters within 65. This study's 38 months is close to that.

Counting every sponsor, half of 38 studies reached it within 48 months; a quarter within 27 and three quarters within 66.

How these figures are worked out, and which studies are left out of them.

Registered
Dec 18, 2015
First posted
Dec 22, 2015
StartActual
Feb 11, 2016
Primary completionActual
May 3, 2019
CompletionActual
May 3, 2019
Results first posted
May 26, 2020
Last update
May 26, 2020
What these dates mean
Start.
When the first participant enrolled; while estimated, when the study expects to open to recruitment.
Primary completion.
When the last participant was examined or treated to collect data for the study's main question, its primary outcome. A study that stopped early gives the date its data collection stopped.
Completion.
When the last participant's last visit took place, for every outcome, secondary ones and side effects included: the end of the study. Often later than primary completion, sometimes the same day.
Actual and Est.
Actual means the registry says the date has happened. Est. (estimated) is a date the sponsor plans or expects. It can still move, and the sponsor is expected to change it to actual once it has passed.
No changes since tracking began. The registry record was last updated on May 26, 2020, before this site started recording changes on Sep 25, 2026. Its history is on ClinicalTrials.gov ↗
11

Registry details

Key details

Study ID
NCT02637856
Lead sponsor
Genentech, Inc.
Responsible party
Sponsor
First posted
Dec 22, 2015
Start date
Feb 11, 2016
Primary completion
May 3, 2019
Completion
May 3, 2019
Results posted
May 26, 2020
Last update
May 26, 2020

Study contacts

Clinical Trials
study director · Hoffmann-La Roche

Oversight

FDA-regulated drug
Yes
FDA-regulated device
No
View the source record on ClinicalTrials.gov ↗

Not currently enrolling

This study is completed, as verified in May 2020. You cannot join it, but the record below documents what was studied.

Follow this study

Get an email when the registry record changes — status, dates, results — or when someone posts here.

Sign in to follow

Discussion

Questions and observations about this study, from anyone following it. Not medical advice, and not a channel to the study team — their contact details are on the registry record.

Sign in to join the discussion. Reading takes no account; posting does. You choose a display name, and a pseudonym is the default.

Nothing here yet. If you are running this trial, taking part in it, or weighing whether to, this is the place to say so.

Studies of the drug tested here: Ocrelizumab

Start the discussion